TODAY'S HEADLINES

FDA approves 2 injectable diabetes drugs

Two new diabetes drugs, both long-acting injectable insulin products, were simultaneously approved by FDA. How they work

Insulin makers accused of price collusion

Congressional representatives recently asked the Department of Justice and the Federal Trade Commission to investigate three insulin makers for price collusion—the latest development in ongoing concerns over insulin prices. Read more

CONTINUING PHARMACY EDUCATION

Addressing unique medication adherence issues for patients with schizophrenia

This month's CE activity, "Addressing unique medication adherence issues for patients with schizophrenia," is open for pharmacists and pharmacy technicians.
The goal of this activity is to educate pharmacists and pharmacy technicians in how to best assist patients in the use of medications to treat schizophrenia.
Pharmacists and pharmacy technicians can earn up to 2 hours of CPE credit for completing this knowledge-based activity from the University of Connecticut School of Pharmacy and Drug Topics. More

EDITOR'S PICK

First generic Nasonex on the market

The manufacturer of the first generic version of Nasonex nasal spray stands to make millions of dollars selling the new drug. Read more

November 30, 2016

Related Articles

FDA approves long-acting insulin drugs

Drug maker pays out millions over EpiPen charges